Examination of phosphorylated tau protein as a PHF-precursor at early stage Alzheimer's disease - PubMed (original) (raw)

Examination of phosphorylated tau protein as a PHF-precursor at early stage Alzheimer's disease

R Y Lai et al. Neurobiol Aging. 1995 May-Jun.

Abstract

Hyperphosphorylated tau protein which can be isolated on the basis of insolubility in 1% sarkosyl (A68-tau fraction) is thought to represent a precursor pool for PHF assembly, associated histologically with neuritic pathology, which feeds into a more resistant tangle-associated PHF pool via cross-linking and proteolysis. We examined these predictions at the earliest detectable stages of neurofibrillary pathology. We report that there is no evidence that neuritic pathology represents an early pathologic stage, no evidence of an association between neuritic pathology and phosphorylated tau, no evidence of selective accumulation of phosphorylated tau at early stages of pathology, and no evidence for a precursor/product relationship between phosphorylated tau and PHFs during progression of pathology. We conclude that altered phosphorylation is a secondary process affecting 5% of PHFs and does not explain PHF assembly in Alzheimer's disease.

PubMed Disclaimer

Cited by

Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau phosphorylation.
Reifert J, Hartung-Cranston D, Feinstein SC. Reifert J, et al. J Biol Chem. 2011 Jun 10;286(23):20797-811. doi: 10.1074/jbc.M111.234674. Epub 2011 Apr 11. J Biol Chem. 2011. PMID: 21482827 Free PMC article.
Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease.
Lai RY, Harrington CR, Wischik CM. Lai RY, et al. Biomolecules. 2016 Apr 8;6(2):19. doi: 10.3390/biom6020019. Biomolecules. 2016. PMID: 27070645 Free PMC article.
Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.
Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, Gertz HJ, Xuereb JH, Hills R, Brayne C, Huppert FA, Paykel ES, McGee M, Jakes R, Honer WG, Harrington CR, Wischik CM. Mukaetova-Ladinska EB, et al. Am J Pathol. 2000 Aug;157(2):623-36. doi: 10.1016/s0002-9440(10)64573-7. Am J Pathol. 2000. PMID: 10934165 Free PMC article.
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ, Davis CS, Staff RT, Vuksanovic V, Ahearn T, Bracoud L, Shamsi K, Marek K, Seibyl J, Riedel G, Storey JMD, Harrington CR, Wischik CM. Wilcock GK, et al. J Alzheimers Dis. 2018;61(1):435-457. doi: 10.3233/JAD-170560. J Alzheimers Dis. 2018. PMID: 29154277 Free PMC article. Clinical Trial.
Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G, Babić Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, Bažadona D, Buée L, de Silva R, Di Giovanni G, Wischik C, Hof PR. Šimić G, et al. Biomolecules. 2016 Jan 6;6(1):6. doi: 10.3390/biom6010006. Biomolecules. 2016. PMID: 26751493 Free PMC article. Review.

Examination of phosphorylated tau protein as a PHF-precursor at early stage Alzheimer's disease - PubMed (original) (raw)